sub:provenance { beldoc:dce:description "Approximately 61,000 statements." ; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ; dce:title "BEL Framework Large Corpus Document" ; pav:authoredBysub:_7 ; pav:version "1.4" . sub:_6prov:value "On the other hand, chemical FAS inhibitors as well as RNA interference-mediated silencing of FAS gene repress Her-2/neu gene expression at the transcriptional level. Moreover, specific FAS blockade synergistically sensitizes breast cancer cells carrying Her-2/neu-oncogene amplification and/or overexpression to trastuzumab-induced cell growth inhibition and apoptotic cell death. Strikingly, FAS inhibition synergistically interacts with trastuzumab in Her-2/neu-negative breast cancer cells engineered to overexpress Her-2/neu, thus suggesting that the molecular linkage between FAS activity and functioning of Her-2/neu cannot be explained only on the basis of a transcriptional repression of Her-2/neu gene promoter." ; prov:wasQuotedFrompubmed:15780499 . sub:_7rdfs:label "Selventa" . sub:assertionprov:hadPrimarySourcepubmed:15780499 ; prov:wasDerivedFrombeldoc: , sub:_6 . }